麻豆传媒

Dr. Christopher Ohl is an infectious disease specialist in Winston Salem, North Carolina and is affiliated with multiple hospitals in the area, including Wake Forest Baptist Health-Lexington Medical Center and Wake Forest Baptist Medical Center. He received his medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice for more than 20 years. 

Dr. Pavia is a pediatric infectious disease expert who can provide expert commentary on vaccines, infectious disease and related trending topics. He has become a trusted source for top national media.

He received his bachelor's degree and medical degree at Brown University. He trained in internal medicine and pediatrics at Dartmouth and the University of Utah. At the Centers for Disease Control and Prevention, Dr. Pavia trained in Public Health Epidemiology as an Epidemic Intelligence Service (EIS) officer and a Preventive Medicine Resident. Additionally, Dr. Pavia completed a fellowship in pediatric and adult infectious diseases at the University of Utah. He joined the faculty at the University of Utah in 1991. In 2003 Dr. Pavia became the George and Esther Gross Presidential Professor and Chief of the Division of Pediatric Infectious Diseases, where he mentors a dynamic and productive team of faculty and fellows. He also serves as Director of Hospital Epidemiology at Primary Children's Hospital and Associate Director of Antimicrobial Stewardship. Dr. Pavia is a member of the Society for Pediatric Research. He is a Fellow of the American Academy of Pediatrics, the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Dr. Pavia is a member of the National Academy of Science Engineering and Medicine Forum on Preparedness. He was recently Vice Chair and Chair of the Program Committee for IDWeek and served two terms on the CDC Board of Scientific Counselors. He has served as a member of the Board of Directors the Infectious Disease Society of America (IDSA) and past chair of the Pandemic Influenza Task Force and past Chair of the National and Global Public Policy Committee. Dr. Pavia served as a member of the National Vaccine Advisory Committee and chaired the Vaccine Safety Working Group, was an inaugural member of the National Biodefense Science Board (NBSB) and chaired the Influenza Working Group, and co-chaired the Personal Preparedness Working Group of the NBSB from 2008-2010. Dr. Pavia has served on several Institute of Medicine Committees including 鈥淎ntivirals for Pandemic Influenza: Guidance on Developing and Distribution and Dispensing System,鈥� and 鈥淧repositioned Medical Countermeasure for the Public,鈥� and is a frequent consultant for CDC. He is an associate Editor of the Sanford Guide to Antimicrobial Therapy and is on the editorial board the Journal of the Pediatric Infectious Disease Society and a reviewer for numerous journals. He has published more than 250 peer-reviewed scientific articles, textbook chapters, reviews and scientific abstracts. His research interests include the epidemiology of influenza and other emerging respiratory infections, pneumonia, vaccine preventable diseases, emerging infections, and HIV/ AIDS, with a particular interest in infections of pregnant women and their children. He has been the principal investigator or co-investigator on grants from the National Institutes of Health, the Bill and Melinda Gates Foundation, and the Centers for Disease Control and Prevention.

Dr. Pavia received his undergraduate and medical degrees from Brown University. He completed his residency at Dartmouth Hitchcock Medical Center and served as Chief Resident. He then served as an officer in the Epidemic Intelligence Service at the Centers for Disease Control and Prevention and completed a residency in Preventive Medicine. He completed fellowship training in pediatric and adult infectious diseases at the University of Utah. Dr. Pavia is currently the George and Esther Gross Presidential Professor at the University of Utah and is Chief of the Division of Pediatric Infectious Diseases. His academic interests include the epidemiology, diagnosis and management of emerging infectious diseases including influenza, respiratory infections and diarrheal diseases. He is also keenly interested in HIV/AIDS and has been involved in HIV clinical care and research since the 1980s.

Dr. Dumois is a Pediatric Infectious Diseases physician at Johns Hopkins All Children's Hospital. He joined the Hospital in 1993. He helps treat children with a variety of infectious diseases and is the director of our International Adoption Clinic. 

Dr. Dumois received his medical degree from the University of South Florida College of Medicine and completed his pediatric residency at All Children's Hospital/USF, serving as chief resident. He completed his fellowship in pediatric infectious disease at Children's National Medical Center, Washington, D.C., in a joint program with the National Institutes of Health. He was awarded the Johns Hopkins All Children鈥檚 Hospital Physician of the Year Clinical Award in 2016.

He plays an active role in continuing medical education, chairing the Planning Committee for the annual Florida Suncoast Pediatric Conference and weekly Pediatric Grand Rounds.

A fellow of the American Academy of Pediatrics, Dr. Dumois is board certified in pediatric infectious diseases. He has received the USF Pediatric Attending Teacher of the Year Award and has been included in Best Doctors in America for more than a decade.

Dr. Ostrosky-Zeichner is a professor of medicine and epidemiology, the chair of the Division of Infectious Diseases, the Vice-Chair of Medicine for Healthcare Quality, and the director of the Laboratory of Mycology Research, at McGovern Medical School (a part of UTHealth Houston). He also serves medical director for epidemiology and antimicrobial stewardship for Memorial Hermann Texas Medical Center and UT Physicians. He also coordinated the CoVID-19 response for UTHealth and its affiliated hospitals and clinics. Dr. Ostrosky-Zeichner obtained his medical degree from Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency at Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and his infectious diseases fellowship at the University of Texas Medical School at Houston and MD Anderson Cancer Center combined fellowship program. Dr. Ostrosky-Zeichner is a fellow of the American College of Physicians, the Infectious Diseases Society of America, the Society of Healthcare Epidemiology of America, and the Academy of the European Confederation of Medical Mycology. He is a Senior Editor for the Journal of Antimicrobial Chemotherapy, as well as an editorial board member of Antimicrobial Agents and Chemotherapy and Clinical Infectious Diseases. He is Vice President of the Mycoses Study Group and Educational Consortium and a Board Member of the International Immunocompromised Host Society. He is also a past chair of the Infectious Diseases Society of America Standards and Practice Guidelines Committee and has been a consultant to the US FDA and CDC. He has advanced training and experience in medical mycology, healthcare epidemiology, emerging infections, antimicrobial stewardship, general and transplant infectious diseases, and healthcare quality and has published over 155 peer-reviewed articles on those topics.

Cathy Troisi is a professor in the Divisions of Management, Policy, and Community Health and Epidemiology at UTHealth Houston School of Public Health and coordinator for the Leadership Studies Concentration. She teaches courses in leadership and public health and is a faculty advisor for the Society for Women and Leadership. She created and manages the undergraduate public health certificate program. Her research interests are in infectious disease epidemiology, and she has research grants in the areas of HIV, viral hepatitis, and improving immunization rates. She holds a BA in Chemistry from the University of Rochester, an MS in Biochemistry from Michigan State University, and a Ph.D. in Epidemiologic Sciences from the University of Michigan. She completed the National Public Health Leadership Training in February 2011. Previously, she served at the Houston Department of Health and Human Services, where she worked on policy development, research collaborations with academic institutions, promotion of public health education for staff, and preparing for health department accreditation. Prior to that, Cathy was assistant director for the Division of Disease Prevention and Control and prior to that, bureau chief for HIV/STD prevention. Prior to joining HDHHS, she was on the faculty of UTHealth and Baylor College of Medicine. Having experience in both academia and practice, her passion, besides infectious diseases, is bridging the gap between these two essential components of public health. Cathy has been involved with APHA since 2004. She is active in the Epidemiology Section and served as programming chair for two years and Epidemiology Section representative to the Governing Council for seven years. She served as chair of the APHA Action Board and co-chair of the Joint Policy Committee. In the past three years, she has had 15 op-eds published in Texas newspapers and given over 100 media interviews on public health issues. Cathy received the APHA Advocacy award in 2015. She is active with the Texas Affiliate as well, having served on the governing council, and receiving the TPHA award for outstanding service in 2010. She is a member of the National Association of County and City Health Officials epidemiology workgroup as well as many local and state public health advisory boards. 

Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children’s Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania. Dr. Offit is an internationally recognized expert in the fields of virology and immunology and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine, and co-editor of the foremost vaccine text, Vaccines. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq®, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation’s Living Proof Project for global health. In 2009, Dr. Offit received the President’s Certificate for Outstanding Service from the American Academy of Pediatrics. In 2011, he received the Humanitarian of the Year Award from the Biologics Industry Organization (BIO), the David E. Rogers Award from the American Association of Medical Colleges, the Odyssey Award from the Center for Medicine in the Public Interest, and was elected to the Institute of Medicine of the National Academy of Sciences. In 2012, Dr. Offit received the Distinguished Medical Achievement Award from the College of Physicians of Philadelphia and the Drexel Medicine Prize in Translational Medicine from the Drexel University College of Medicine. In 2013, he received the Maxwell Finland award for Outstanding Scientific Achievement from the National Foundation for Infectious Diseases, the Distinguished Alumnus award from the University of Maryland School of Medicine, and the Innovators in Health Award from the Group Health Foundation. In 2014, he was elected to the board of trustees at the College of Physicians in Philadelphia, and in 2015, he was elected to the American Association of Physicians and the American Academy of Arts and Sciences as well as being named as a Fellow for the Pediatric Infectious Diseases Society and the American Academy for the Advancement of Science. In 2016, Dr. Offit received the Franklin Founder Award by the City of Philadelphia, The Porter Prize from the University of Pittsburgh School of Public Health, and the Jonathan E. Rhoads Medal for Distinguished Service to Medicine from The American Philosophical Society. In 2017, he received the Defensor Scientiae Award and an Honorary Doctor of Science degree from The University of the Sciences in Philadelphia. In 2018, he was named to the Alpha Omega Alpha Honor Society at the University of Maryland School of Medicine.

Julia Shaklee Sammons, MD, MSCE, is the Hospital epidemiologist and Medical Director of the Department of Infection Prevention and Control at Children's Hospital of Philadelphia.

Areas of Expertise: Prevention of healthcare-associated infections, Epidemiology of pediatric C. difficile infection, Change management and implementation of quality improvement initiatives

Medical School
MD - Vanderbilt University School of Medicine 

Internship
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA

Residency
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA

Fellowship
Pediatric Infectious Diseases - The Children's Hospital of Philadelphia, Philadelphia, PA

Board Certification
Pediatric Infectious Diseases
Pediatrics

Graduate Degree
Master of Science in Clinical Epidemiology (MSCE) - University of Pennsylvania, Philadelphia, PA

Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.

Bindu Mayi, M.Sc., Ph.D., is a professor of microbiology in NSU鈥檚 Dr. Kiran C. Patel College of Osteopathic Medicine, where she teaches infectious diseases to students in the medical, public health, and other allied health fields. In addition to her teaching responsibilities, Dr. Mayi is committed to promoting Infection Prevention as well as Antimicrobial Stewardship. 

She has been a spokesperson on various infections and has appeared on multiple panels attended by healthcare professionals and public officials, including representatives from the CDC. Dr. Mayi has provided comment and insight into a myriad of topics, including the Zika virus, the life threatening condition sepsis and necrotizing fasciitis (a.k.a. flesh eating disease). Most recently she has provided expert guidance and insight into the COVID-19 pandemic. She is well versed in working with the media (print and broadcast) and is comfortable on camera or, nowadays, via Zoom or Skype. She has also had several guest editorials published in newspapers across Florida.

Prior to her NSU affiliation, Dr. Mayi worked in antibiotic resistance research as well as cancer nanotechnology research. Dr. Mayi is passionate about medical education, especially prevention of infectious diseases. In 2008, Dr. Mayi was one of 80 women winners of the 鈥極-Whitehouse Leadership Project鈥�, where her project was prevention of MRSA in U.S. hospitals. 

Eleanor (Pitt) Wilson, a native of Louisville, Kentucky, attended medical school at the Johns Hopkins Medical Institute, in Baltimore, Maryland. She completed residency training in Internal Medicine at Vanderbilt University Medical Center in Nashville, Tennessee, and subspecialty fellowship training in Infectious Disease at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland. She obtained her Masters in Clinical Research as part of a collaborative program between Duke University and the National Institutes of Health.

Despite dramatic improvements in the life expectancy of persons with human immunodeficiency virus (HIV) infection, non-AIDS events such as liver disease and cancer are now the predominant causes of morbidity and mortality in treated populations. Markers of immune activation have been associated with HIV disease progression, predict mortality, and persist despite effective antiretroviral therapy; patients co-infected with hepatitis C virus (HCV) and HIV have higher levels of immune activation than those infected with HIV or HCV alone and are at increased risk for mortality due to liver and cardiovascular disease. Understanding the role of immune activation in the rapid progression of hepatic fibrosis in patients with HIV and HCV co-infection will help us to address this burgeoning public health problem, and at the same time, understand how the clearance of a chronic viral infection affects global immune activation and what can be done to augment treatment responses and improve rates of viral clearance and resolution of hepatic fibrosis.

My scientific interests and investigations have focused on the alterations to innate and adaptive immunity in chronic viral infections, including HIV and viral hepatitis. Beginning with my work with Dr. Robert Siliciano during medical school investigating HIV persistence in latently infected T cell subsets, extending through my fellowship research with Dr. Irini Sereti regarding the mechanisms connecting soluble and cellular immune activation with clinical outcomes in HIV, and now working with Dr. Shyam Kottilil on the reconstitution of innate and adaptive immunology following clearance of HCV, I have developed expertise in the translational research techniques required to address these questions. As a Principal Investigator and Lead Associate Investigator on multiple clinical trials in the beginning of my career at the National Institute of Allergy and Infectious Diseases and now at the Institute of Human Virology, I am eager to continue working on ways to improve the health of patients with chronic viral infections and advanced liver disease.

Mara Aspinall is an expert in biomedical diagnostics, biomedicine and medical diagnostic devices.

She is a professor of practice in the College of Health Solutions and the co-founder of the Biomedical Diagnostics program within the college.

Throughout her career, Aspinall has spearheaded initiatives to educate payers and policymakers on genomics and personalized medicine.

In addition to her position at ASU, Aspinall is the co-founder and managing director of BlueStone Venture Partners and the managing director of Health Catalysts Group.

Professor Adam Finn is based in Bristol鈥檚 Children Vaccine Centre where his focus is on infectious diseases and immunology. His particular specialism is on vaccines for children: how they work and, in particular, how immunisation schemes can impact the transmission of infections. Professor Finn leads the Bristol COVID Emergency Research Group, UNCOVER, which pools the combined expertise of researchers to understand and combat the many health and societal challenges raised by COVID-19. He also chairs the WHO European Technical Advisory Group of Experts on Immunisation and he is a member of the UK Department of Health鈥檚 Joint Committee on Vaccines and Immunisation.

Education
1980 - MSc Medical Sciences and History of Art, University of Cambridge 
1983 - MD Clinical Medicine and Surgery, University of Oxford

Affiliations
Member of the British Society for Immunology
Member of the British Inflammation Research Association 
Member of the European Society for Paediatric Infectious Diseases

Accomplishments
2009 - Bill Marshall Award, European Society for Paediatric Infectious Diseases, 
2010 - Sparks Children鈥檚 Medical Research Charity, Excellence in Medical Research Award, 
2015 - Clinical Excellence Award NHS, UK Dept Health (Gold)

Dr Ellen Brooks Pollock is an expert mathematical modelling and epidemiology. She is based at the Bristol Veterinary School where her focus is on using infectious disease modelling, disease dynamic theory and epidemiological data to answer applied questions about the transmission and control of infectious diseases. During the COVID-19 pandemic she collaborated with other academics to investigate mapping and mitigation strategies within schools, as well as exploring quantitative predictions in response to the evolving nature of the pandemic. She has also studied the national prevalence of Hepatitis B and Zoonotic Tuberculosis. In tandem with her teaching and research commitments, Dr Brooks-Pollock is focused on developing tools for communicating about the nature of infectious diseases to non-modellers, particularly with a view to answering policy-relevant questions. She has featured on BBC 麻豆传媒 and BBC Radio 4 Today, as well as 麻豆传媒night, Countryfile and Farming Today. Dr Brooks-Pollock is also a member of the government鈥檚 SPI-M modelling group, as well as the SAGE-subgroup on children and schools,鈥痑 member of the JUNIPER (Joint UNIversities Pandemic and Epidemiological Research) consortium, and a member of the UK government鈥檚 Animal and Plant Health Agency鈥檚 National Expert Group (NEG) for outbreaks.

Education
2003 - MSci Mathematics, University College London
2008 - PhD Maths/Biology, University of Warwick

Affiliations
SPI-M modelling group: Member, JUNIPER (Joint UNIversities Pandemic and Epidemiological Research) consortium : Member, Animal and Plant Health Agency鈥檚 National Expert Group : Member

Dr. Huang鈥檚 research focuses on the clinical epidemiology of highly antibiotic-resistant organisms including estimating the risk for infection and assessing practical means for prevention. Dr. Huang鈥檚 work involves studying the risks of healthcare-associated transmission of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE), including both short and long-term sequelae due to these pathogens within and beyond the hospital stay. Her scope of research also includes an evaluation of inter-facility spread and containment of these pathogens, including the intersection of preventative measures on hospital networks, affiliated nursing homes, and surrounding communities. She has evaluated several strategies to mitigate transmission and disease, including active surveillance and institution of contact precautions, enhanced environmental cleaning, and, most recently, leading several large individual and cluster randomized trials of decolonization to reduce multidrug-resistant organisms and healthcare-associated infections.

Dr. Huang has also built a population laboratory in a large metropolitan county in Southern California (Orange County, CA). She has performed detailed data collection across all hospitals and nursing homes in this county, including extensive details on inter-facility patient sharing, infection control practices, and ICUs, non-ICUs, and nursing homes estimates of pathogen burden in this county. These detailed population data are the foundation for a dynamic transmission model of Orange County facilities and communities built through the NIH Models of Infectious Disease Agent Study (MIDAS) collaborative. This model will allow simulation of intervention strategies as well as prediction of future trends in transmission and disease burden for MRSA and other pathogens.
Beyond MRSA, Dr. Huang is broadly interested in the measurement and prevention of healthcare associated infections. She has evaluated more efficient ways to look at relative hospital rankings using administrative data, and has balanced this with rigorous in depth assessments related to accuracy and completeness of reporting. She has specific interests in the use of automated hospital and claims data to assess pathogen clusters and surgical site infections.

Dr. R. Wesley Farr, Lecturer, teaches environmental health, aerospace toxicology, global health, and infectious diseases for the UWF Department of Public Health

Farr is a physician with specialties in Infectious Diseases, Tropical Medicine, Internal Medicine, and Aerospace Medicine.  He continues part-time work in Infectious Diseases.

He was previously on the Infectious Diseases faculty at West Virginia University where he was Director of the International Health program, Director of the Clinical Tropical Medicine and Parasitology Course, and Activity Director of the annual AIDS in West Virginia Conference.

He retired from the US Navy in 2015 after serving as Senior Medical Officer on the USS Harry S Truman, Director of the Military Tropical Medicine Course, and Executive Officer of the Navy and Marine Corps Public Health Center.  He was a medical advisor to the ANA Regional Hospital in Mazar-e-Sharif, Afghanistan.

Before coming to UWF in 2018, he worked at Joint Ambulatory Care Center (VA) and the AIDS Healthcare Foundation.

He received his bachelor鈥檚 degree in Biology, Doctor of Medicine degree, and Masters in Public Health degree from West Virginia University.

Dr. Mullin鈥檚 research focuses on the role of tight junctional leakiness in cancer, aging, infectious diseases and inflammatory diseases in the GI tract, respiratory tract, the oral epithelium and the lining of the uterus. He also is investigating the effect of micronutrient consumption/nutrition on reducing epithelial barrier leak, and the role of barrier (junctional) leak in infectious diseases such as Ebola, Marburg and coronaviruses. He is a professor for the Lankenau Institute for Medical Research, part of Main Line Health.

Strategic decision making, risk analysis, lone-wolf terrorists, infectious diseases, malaria, multicriteria decision analysis

Professor Montibeller is available to discuss operation management, which includes sporting event such as Olympics and World Cups. A decision scientist, Gilberto is an experienced expert on behavioural operations.

Katherine Baumgarten, MD, is board certified in internal medicine and infectious diseases, and has served as Ochsner Health medical director of infection prevention since 2008. Her expertise includes health care safety and clinical infectious diseases, along with emerging infections and adult vaccines. She has been interviewed by 麻豆传媒week magazine, CNN and numerous local outlets on COVID-19, measles and bird flu, among other topics. 
Dr. Baumgarten is a fellow of both the American College of Physicians and the Infectious Diseases Society of America. She is a member of the Society for Healthcare Epidemiology of America and the American Board of Internal Medicine.
A New Orleans native, she attended Washington and Lee University in Lexington, Virginia, and earned a medical degree from Louisiana State University Health Sciences Center - New Orleans. She completed an internship and residency at the University of California at San Francisco and completed an infectious diseases fellowship at Ochsner Medical Foundation in New Orleans.

Amanda Martinot, D.V.M., M.P.H., Ph.D., DACVP, is assistant professor in the Department of Infectious Diseases and Global Health. She joined Cummings School of Veterinary Medicine in 2019 as an assistant adjunct professor.
Martinot is a veterinarian-scientist and board-certified veterinary pathologist (anatomic) who specializes in animal models of infectious diseases of global health importance such as tuberculosis (TB), HIV, and SARS CoV-2. With over 15 years of experience in TB biology, her independent research focuses on preclinical animal models for TB vaccine development and the basic immunology and virulence determinants underlying the TB host-pathogen interaction. As a veterinary pathologist, Martinot has expertise in animal models for infectious disease pathogenesis and drug and vaccine discovery research, with a focus on nonhuman primate infectious disease pathology.
Martinot received her veterinary degree from the University of Florida College of Veterinary Medicine in 2003. She went on to study the epidemiology of infectious diseases and global health at the University of North Carolina at Chapel Hill, where she completed her M.P.H. in 2006. She specialized in comparative pathology and infectious diseases by completing her pathology residency training at Harvard Medical School and New England Primate Research Center, and her Ph.D. at Harvard T. H. Chan School of Public Health, where she studied the microbiology and immunopathology of Mycobacterium tuberculosis infection. She studied vaccine immunology during her postdoctoral studies at Beth Israel Deaconess Medical Center and has contributed to vaccine development efforts for TB, Zika virus, and most recently SARS-CoV-2.